Core Viewpoint - Heng Rui Medicine (600276.SH) has received approval from the National Medical Products Administration for multiple clinical trial applications, indicating a significant advancement in its drug development pipeline [1] Group 1: Clinical Trials - The company and its subsidiaries have been granted approval for clinical trials of several injectable drugs, including SHR-9839(sc), SHR-A2009, SHR-1826, HRS-4642, and others [1] - A specific trial will focus on the safety, tolerability, and efficacy of SHR-9839(sc) in combination with anti-tumor drugs in solid tumor subjects, categorized as an IB/II phase study [1]

Core Viewpoint - Heng Rui Medicine (600276.SH) has received approval from the National Medical Products Administration for multiple clinical trial applications, indicating a significant advancement in its drug development pipeline [1] Group 1: Clinical Trials - The company and its subsidiaries, including Suzhou Shengdiya Biopharmaceutical Co., Ltd., Shanghai Heng Rui Medicine Co., Ltd., and Shanghai Shengdi Medicine Co., Ltd., have been granted clinical trial approval for several injectable drugs [1] - The approved drugs include SHR-9839(sc), SHR-A2009, SHR-1826, HRS-4642 injection, Adebali monoclonal antibody injection, and others [1] - A specific focus is on the Phase IB/II study of SHR-9839(sc) in combination with anti-tumor drugs, targeting safety, tolerability, and efficacy in solid tumor subjects [1]

Core Viewpoint - Heng Rui Medicine (600276.SH) has received approval from the National Medical Products Administration for multiple clinical trial applications, indicating a significant advancement in its drug development pipeline [1] Group 1: Clinical Trials - The company and its subsidiaries, including Suzhou Shengdiya Biopharmaceutical Co., Ltd., Shanghai Heng Rui Medicine Co., Ltd., and Shanghai Shengdi Medicine Co., Ltd., have been granted clinical trial approval for several injectable drugs [1] - The approved drugs include SHR-9839(sc), SHR-A2009, SHR-1826, HRS-4642 injection, Adalimumab injection, and others, which will undergo clinical trials in the near future [1] - Specifically, a Phase IB/II study will be conducted to evaluate the safety, tolerability, and efficacy of SHR-9839(sc) in combination with anti-tumor drugs in patients with solid tumors [1]

Core Viewpoint - Heng Rui Medicine announced the approval of multiple clinical trial applications for new drugs by the National Medical Products Administration, indicating a significant advancement in its drug development pipeline [1] Group 1: Clinical Trials - The company and its subsidiaries received approval for clinical trials of several injectable drugs, including SHR-9839(sc), SHR-A2009, SHR-1826, HRS-4642, and others [1] - A specific focus is on the Phase I/II study of SHR-9839(sc) in combination with anti-tumor drugs for safety, tolerability, and efficacy in solid tumor patients [1]

Core Viewpoint - Heng Rui Medicine's subsidiary, Guangdong Heng Rui Medicine Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of SHR-1139 injection, aimed at treating necrotizing pyoderma, marking a significant step in the company's drug development efforts [1] Group 1 - SHR-1139 injection is a biopharmaceutical independently developed by Heng Rui Medicine [1] - There are currently no similar drugs approved for market in both domestic and international markets [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 江蘇恒瑞醫藥股份有限公司 呈交日期： 2025年11月21日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | A | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | 600276 | 說明 | A股（於上海證券交易所上市） | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/8/21 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2025 年 月 8 | 8 | 20 | 日~2026 | 年 | 月 | 19 日 | | 预计回购金额 | 100,000万元~200,000万元 | | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | | | | | | □用于转换公司可转债 □为维护公司价值及股东权益 | | | | | | | | 累计已回购股数 | 889.87万股 | | | | | | | | 累计已回购股数占总股本比例 | 0.13% | | | | | | | | 累计已回购金额 | 59,521.63万元 | | | | | | | | 实际回购价格区间 | 59.32元/股~70.00/元/股 | | | | | | | ...

证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025-183 江苏恒瑞医药股份有限公司 关于获得药物临床试验批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，江苏恒瑞医药股份有限公司（以下简称"公司"）及子公司苏州盛迪 亚生物医药有限公司、上海恒瑞医药有限公司、上海盛迪医药有限公司收到国家 药品监督管理局（以下简称"国家药监局"）核准签发关于注射用 SHR-9839(sc)、 注射用 SHR-A2009、注射用 SHR-1826、HRS-4642 注射液、阿得贝利单抗注射液、 注射用瑞康曲妥珠单抗、注射用 SHR-A2102、HRS-7058 胶囊和 HRS-7058 片的《药 物临床试验批准通知书》，将于近期开展临床试验。现将相关情况公告如下： 药品 名称 注射用 SHR-9839（sc） 注射用 SHR-A2009 注射用 SHR-1826 HRS-4642 注射液 阿得贝利单 抗注射液 注射用瑞康 曲妥珠单抗 注射用 SHR-A2102 HRS-7058 胶囊 HRS-7058 片 剂 ...

江苏恒瑞医药股份有限公司 关于获得药物临床试验批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025-182 剂 型：注射剂 申请事项：临床试验 受 理 号：CXSL2500704 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，2025 年 8 月 15 日受理的 SHR-1139 注射液临床试验申请符合药品注册的有关要求，同 意本品开展坏疽性脓皮病的临床试验。 二、药物的其他情况 三、风险提示 近日，江苏恒瑞医药股份有限公司（以下简称"公司"）子公司广东恒瑞医 药有限公司收到国家药品监督管理局（以下简称"国家药监局"）核准签发关于 SHR-1139 注射液的《药物临床试验批准通知书》，将于近期开展临床试验。现 将相关情况公告如下： 一、药物的基本情况 药物名称：SHR-1139 注射液 SHR-1139 注射液是公司自主研发的一种治疗用生物制品，经查询，目前国 内外尚无同类药物获批上市。截至目前，SHR-1139 注射液相关项目累计 ...

格隆汇11月21日丨恒瑞医药(01276.HK)发布公告，2025年11月21日耗资人民币1488万元回购25万股A 股，回购价格每股59.32-59.72元。 ...